|
1
|
Ostrom QT, Cote DJ, Ascha M, Kruchko C and
Barnholtz-Sloan JS: Adult glioma incidence and survival by race or
ethnicity in the United States from 2000 to 2014. JAMA Oncol.
4:1254–1262. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Yang P, Wang Y, Peng X, You G, Zhang W,
Yan W, Bao Z, Wang Y, Qiu X and Jiang T: Management and survival
rates in patients with glioma in China (2004–2010): A retrospective
study from a single-institution. J Neurooncol. 113:259–266. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhao YD, Zhang QB, Chen H, Fei XF, Shen
YT, Ji XY, Ma JW, Wang AD, Dong J, Lan Q, et al: Research on human
glioma stem cells in China. Neural Regen Res. 12:1918–1926. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Li K, Lu D, Guo Y, Wang C, Liu X, Liu Y
and Liu D: Trends and patterns of incidence of diffuse glioma in
adults in the United States, 1973–2014. Cancer Med. 7:5281–5290.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cloos PA, Christensen J, Agger K, Maiolica
A, Rappsilber J, Antal T, Hansen KH and Helin K: The putative
oncogene GASC1 demethylates tri- and dimethylated lysine 9 on
histone H3. Nature. 442:307–311. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Liu G, Bollig-Fischer A, Kreike B, van de
Vijver MJ, Abrams J, Ethier SP and Yang ZQ: Genomic amplification
and oncogenic properties of the GASC1 histone demethylase gene in
breast cancer. Oncogene. 28:4491–4500. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Berdel B, Nieminen K, Soini Y, Tengström
M, Malinen M, Kosma VM, Palvimo JJ and Mannermaa A: Histone
demethylase GASC1 - a potential prognostic and predictive marker in
invasive breast cancer. BMC Cancer. 12:5162012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sun LL, Holowatyj A, Xu XE, Wu JY, Wu ZY,
Shen JH, Wang SH, Li EM, Yang ZQ and Xu LY: Histone demethylase
GASC1, a potential prognostic and predictive marker in esophageal
squamous cell carcinoma. Am J Cancer Res. 3:509–517.
2013.PubMed/NCBI
|
|
9
|
Uimonen K, Merikallio H, Pääkkö P, Harju
T, Mannermaa A, Palvimo J, Kosma VM and Soini Y: GASC1 expression
in lung carcinoma is associated with smoking and prognosis of
squamous cell carcinoma. Histol Histopathol. 29:797–804.
2014.PubMed/NCBI
|
|
10
|
Kupershmit I, Khoury-Haddad H, Awwad SW,
Guttmann-Raviv N and Ayoub N: KDM4C (GASC1) lysine demethylase is
associated with mitotic chromatin and regulates chromosome
segregation during mitosis. Nucleic Acids Res. 42:6168–6182. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ozaki Y, Fujiwara K, Ikeda M, Ozaki T,
Terui T, Soma M, Inazawa J and Nagase H: The oncogenic role of
GASC1 in chemically induced mouse skin cancer. Mamm Genome.
26:591–597. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sudo G, Kagawa T, Kokubu Y, Inazawa J and
Taga T: Increase in GFAP-positive astrocytes in histone demethylase
GASC1/KDM4C/JMJD2C hypomorphic mutant mice. Genes Cells.
21:218–225. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Movassaghian S, Xie Y, Hildebrandt C,
Rosati R, Li Y, Kim NH, Conti DS, da Rocha SR, Yang ZQ and Merkel
OM: Post-transcriptional regulation of the GASC1 oncogene with
active tumor-targeted siRNA-nanoparticles. Mol Pharm. 13:2605–2621.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jia R, Yang L, Yuan X, Kong J, Liu Y, Yin
W, Gao S and Zhang Y: GASC1 promotes stemness of esophageal
squamous cell carcinoma via NOTCH1 promoter demethylation. J Oncol.
2019:16210542019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Natsume A, Kinjo S, Yuki K, Kato T, Ohno
M, Motomura K, Iwami K and Wakabayashi T: Glioma-initiating cells
and molecular pathology: Implications for therapy. Brain Tumor
Pathol. 28:1–12. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Roussel MF and Hatten ME: Cerebellum
development and medulloblastoma. Curr Top Dev Biol. 94:235–282.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yang X, Xiao Z, Du X, Huang L and Du G:
Silencing of the long non-coding RNA NEAT1 suppresses glioma
stem-like properties through modulation of the miR-107/CDK6
pathway. Oncol Rep. 37:555–562. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wesseling P and Capper D: WHO 2016
Classification of gliomas. Neuropathol Appl Neurobiol. 44:139–150.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Weichbrod RH, Thompson GA and Norton JN:
Management of Animal Care and Use Programs in Research, Education,
and Testing. CRC Press/Taylor & Francis; Boca Raton, FL:
2018
|
|
20
|
Chen Y: Scratch wound healing assay. Bio
Protoc. 2:e1002012.
|
|
21
|
Bai J, Varghese J and Jain R: Adult glioma
WHO classification update, genomics, and imaging: What the
radiologists need to know. Top Magn Reson Imaging. 29:71–82. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Delev D, Heiland DH, Franco P, Reinacher
P, Mader I, Staszewski O, Lassmann S, Grau S and Schnell O:
Surgical management of lower-grade glioma in the spotlight of the
2016 WHO classification system. J Neurooncol. 141:223–233. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cordeiro BM, Oliveira ID, Alves MT,
Saba-Silva N, Capellano AM, Cavalheiro S, Dastoli P and Toledo SR:
SHH, WNT, and NOTCH pathways in medulloblastoma: When cancer stem
cells maintain self-renewal and differentiation properties. Childs
Nerv Syst. 30:1165–1172. 2014.PubMed/NCBI
|
|
24
|
Xu A, Yang H, Gao K, Zhan Z, Song Z, Huang
T and Song Y: Expression profiles and prognostic significance of
WNT family members in glioma via bioinformatic analysis. Biosci
Rep. 40:402020. View Article : Google Scholar
|
|
25
|
Shahi MH, Farheen S, Mariyath MP and
Castresana JS: Potential role of Shh-Gli1-BMI1 signaling pathway
nexus in glioma chemoresistance. Tumour Biol. 37:15107–15114. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yi L, Zhou X, Li T, Liu P, Hai L, Tong L,
Ma H, Tao Z, Xie Y, Zhang C, et al: Notch1 signaling pathway
promotes invasion, self-renewal and growth of glioma initiating
cells via modulating chemokine system CXCL12/CXCR4. J Exp Clin
Cancer Res. 38:3392019. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Morovic W and Budinoff CR: Epigenetics: A
new frontier in probiotic research. Trends Microbiol.
2020.PubMed/NCBI
|
|
28
|
Wimalasena VK, Wang T, Sigua LH, Durbin AD
and Qi J: Using chemical epigenetics to target cancer. Mol Cell.
78:1086–1095. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Foltz G, Yoon JG, Lee H, Ma L, Tian Q,
Hood L and Madan A: Epigenetic regulation of wnt pathway
antagonists in human glioblastoma multiforme. Genes Cancer.
1:81–90. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Nagarajan RP and Costello JF: Epigenetic
mechanisms in glioblastoma multiforme. Semin Cancer Biol.
19:188–197. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Danussi C and Huse JT: Novel insights into
the epigenetics of diffuse glioma. Mol Cell Oncol. 5:e14720552018.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Gusyatiner O and Hegi ME: Glioma
epigenetics: From subclassification to novel treatment options.
Semin Cancer Biol. 51:50–58. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Buczkowicz P and Hawkins C: Pathology,
molecular genetics, and epigenetics of diffuse intrinsic pontine
glioma. Front Oncol. 5:1472015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kallestad L, Christensen K, Woods E and
Milavetz B: Transcriptional repression is epigenetically marked by
H3K9 methylation during SV40 replication. Clin Epigenetics.
6:212014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yang ZQ, Imoto I, Fukuda Y, Pimkhaokham A,
Shimada Y, Imamura M, Sugano S, Nakamura Y and Inazawa J:
Identification of a novel gene, GASC1, within an amplicon at
9p23-24 frequently detected in esophageal cancer cell lines. Cancer
Res. 60:4735–4739. 2000.PubMed/NCBI
|
|
36
|
Hélias C, Struski S, Gervais C, Leymarie
V, Mauvieux L, Herbrecht R and Lessard M: Polycythemia vera
transforming to acute myeloid leukemia and complex abnormalities
including 9p homogeneously staining region with amplification of
MLLT3, JMJD2C, JAK2, and SMARCA2. Cancer Genet Cytogenet.
180:51–55. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Italiano A, Attias R, Aurias A, Pérot G,
Burel-Vandenbos F, Otto J, Venissac N and Pedeutour F: Molecular
cytogenetic characterization of a metastatic lung sarcomatoid
carcinoma: 9p23 neocentromere and 9p23-p24 amplification including
JAK2 and JMJD2C. Cancer Genet Cytogenet. 167:122–130. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Sun Z, Wang L, Zhou Y, Dong L, Ma W, Lv L,
Zhang J and Wang X: Glioblastoma stem cell-derived exosomes enhance
stemness and tumorigenicity of glioma cells by transferring Notch1
protein. Cell Mol Neurobiol. 40:767–784. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zhang L, Yu H, Yuan Y, Yu JS, Lou Z, Xue Y
and Liu Y: The necessity for standardization of glioma stem cell
culture: A systematic review. Stem Cell Res Ther. 11:842020.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Engh JA: Notch1 identified as a prognostic
factor for glioma patients. Neurosurgery. 68:N22–N23. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Jiang L, Wu J, Chen Q, Hu X, Li W and Hu
G: Notch1 expression is upregulated in glioma and is associated
with tumor progression. J Clin Neurosci. 18:387–390. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Li J, Cui Y, Gao G, Zhao Z, Zhang H and
Wang X: Notch1 is an independent prognostic factor for patients
with glioma. J Surg Oncol. 103:813–817. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Sun ZF, Wang L, Gu F, Fu L, Li WL and Ma
YJ: Expression of Notch1, MMP-2 and MMP-9 and their significance in
glioma patients. Zhonghua Zhong Liu Za Zhi. 34:26–30. 2012.(In
Chinese). PubMed/NCBI
|
|
44
|
Yu X, Zhang W, Ning Q and Luo X:
MicroRNA-34a inhibits human brain glioma cell growth by
down-regulation of Notch1. J Huazhong Univ Sci Technolog Med Sci.
32:370–374. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Ming J, Sun B, Li Z, Lin L, Meng X, Han B,
Wang R, Wu P, Li J, Cai J, et al: Aspirin inhibits the SHH/GLI1
signaling pathway and sensitizes malignant glioma cells to
temozolomide therapy. Aging (Albany NY). 9:1233–1247. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Qiang L, Wu T, Zhang HW, Lu N, Hu R, Wang
YJ, Zhao L, Chen FH, Wang XT, You QD, et al: HIF-1α is critical for
hypoxia-mediated maintenance of glioblastoma stem cells by
activating Notch signaling pathway. Cell Death Differ. 19:284–294.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Hu YY, Fu LA, Li SZ, Chen Y, Li JC, Han J,
Liang L, Li L, Ji CC, Zheng MH, et al: Hif-1α and Hif-2α
differentially regulate Notch signaling through competitive
interaction with the intracellular domain of Notch receptors in
glioma stem cells. Cancer Lett. 349:67–76. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Espinoza I and Miele L: Notch inhibitors
for cancer treatment. Pharmacol Ther. 139:95–110. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Locatelli M and Curigliano G: Notch
inhibitors and their role in the treatment of triple negative
breast cancer: Promises and failures. Curr Opin Oncol. 29:411–427.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Komori T: Brain Tumor. Brain Nerve.
72:399–405. 2020.(In Japanese). PubMed/NCBI
|
|
51
|
Yang ZQ, Imoto I, Pimkhaokham A, Shimada
Y, Sasaki K, Oka M and Inazawa J: A novel amplicon at 9p23-24 in
squamous cell carcinoma of the esophagus that lies proximal to
GASC1 and harbors NFIB. Jpn J Cancer Res. 92:423–428. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Marino S: Medulloblastoma: Developmental
mechanisms out of control. Trends Mol Med. 11:17–22. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
de Bont JM, Packer RJ, Michiels EM, den
Boer ML and Pieters R: Biological background of pediatric
medulloblastoma and ependymoma: A review from a translational
research perspective. Neuro Oncol. 10:1040–1060. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Mishra S: CSNK1A1 and Gli2 as novel
targets identified through an integrative analysis of gene
expression data, protein-protein interaction and pathways networks
in glioblastoma tumors: Can these two be antagonistic proteins?
Cancer Inform. 13:93–108. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Louis DN, Perry A, Reifenberger G, von
Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD,
Kleihues P and Ellison DW: The 2016 world health organization
classification of tumors of the central nervous system: A summary.
Acta Neuropathol. 131:803–820. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Vora P, Seyfrid M, Venugopal C, Qazi MA,
Salim S, Isserlin R, Subapanditha M, OFarrell E, Mahendram S, Singh
M, et al: Bmi1 regulates human glioblastoma stem cells through
activation of differential gene networks in CD133+ brain
tumor initiating cells. J Neurooncol. 143:417–428. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Chang S, Yim S and Park H: The cancer
driver genes IDH1/2, JARID1C/KDM5C, and UTX/KDM6A: Crosstalk
between histone demethylation and hypoxic reprogramming in cancer
metabolism. Exp Mol Med. 51:1–17. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Sanchez-Martin M: Brain tumour stem cells:
Implications for cancer therapy and regenerative medicine. Curr
Stem Cell Res Ther. 3:197–207. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Jia R, Mi Y, Yuan X, Kong D, Li W, Li R,
Wang B, Zhu Y, Kong J, Ma Z, et al: GASC1-adapted neoadjuvant
chemotherapy for resectable esophageal squamous cell carcinoma: A
prospective clinical biomarker trial. J Oncol. 2020:16078602020.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Mintz A and Debinski W: Cancer
genetics/epigenetics and the X chromosome: Possible new links for
malignant glioma pathogenesis and immune-based therapies. Crit Rev
Oncog. 11:77–95. 2000. View Article : Google Scholar : PubMed/NCBI
|
